Vedolizumab

Red

Brand Name(s):Entyvio

Indication:Ulcerative Colitis and Crohn’s Disease, moderate to severe

Rationale:1,2

Considered:Jul-14

Review Date:Sep-20

Comments:
NICE TA352
Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Full details at:http://www.nice.org.uk/guidance/ta352/resources/guidance-vedolizumab-for-treating-moderately-to-severely-active-crohns-disease-after-prior-therapy-pdf
Aug 2015

…………………………
Vedolizumab for treating moderately to severely active ulcerative colitis
Full guidance at: http://www.nice.org.uk/guidance/ta342/resources/guidance-vedolizumab-for-treating-moderately-to-severely-active-ulcerative-colitis-pdf
June 2015